Related Experiment Video
Updated: Apr 18, 2026
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
23.6K
Lung CD200 Receptor Activation Abrogates Airway Hyperresponsiveness in Experimental Asthma
Jean-François Lauzon-Joset1, Anick Langlois1, Laetitia J A Lai1
1Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec; and Department of Medicine, Laval University, Quebec City, Quebec, Canada.
American Journal of Respiratory Cell and Molecular Biology
|January 9, 2015
Summary
Recombinant CD200 (rCD200) therapy effectively reduced airway hyperresponsiveness in an asthma model. This treatment modulated immune cell accumulation and cytokine profiles, restoring lung homeostasis.
Area of Science:
- Immunology
- Respiratory Medicine
- Pharmacology
Background:
- Allergic asthma involves dysregulated immune responses to harmless antigens.
- The CD200-CD200 receptor pathway regulates inflammation; CD200 is downregulated in asthma patients.
- Restoring lung homeostasis is crucial for managing allergic asthma.
Purpose of the Study:
- To investigate if local delivery of recombinant CD200 (rCD200) can restore lung homeostasis in an experimental asthma model.
- To assess the anti-inflammatory effects of rCD200 on airway hyperresponsiveness and immune cell infiltration.
Main Methods:
- Ovalbumin (OVA)-sensitized Brown Norway rats received intratracheal rCD200 before OVA challenge.
- Airway responsiveness to methacholine was measured.
- Cell recruitment and cytokine levels (IL-13, IL-10) in bronchoalveolar lavages were analyzed.
- Accumulation of dendritic cells (DCs) and T cells in lungs and lymph nodes was assessed.
Main Results:
- rCD200 administration abolished airway hyperresponsiveness in sensitized rats.
- rCD200 significantly reduced OVA-induced lung accumulation of myeloid DCs, CD4(+) T cells, and T helper type 2 cells.
- A decrease in IL-13 and an increase in IL-10 were observed in bronchoalveolar lavages.
Conclusions:
- Local delivery of rCD200 inhibits airway hyperresponsiveness in a model of asthma.
- rCD200 acts via a mechanism involving local T cell response modulation and altered cytokine milieu.
- This suggests rCD200 as a potential therapeutic agent for allergic asthma.
More Related Videos
Related Concept Videos
01:28Asthma I: Introduction
3
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
3
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:26Asthma-II: Pathophysiology and Classification
5.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
5.0K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
2.2K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.2K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K